Since 2020, Hanna Glasebach has been a research associate in the Cell and Tissue Technologies Group at Fraunhofer IGB. She studied biochemistry at the Eberhard Karls University of Tübingen and has been working on the establishment of a 3D in-vitro skin model for the validation of new targets for the treatment of psoriasis since then.
Professional career |
|
| Since 2020 | Research associate in the Innovation Field Cell and Tissue Technologies at Fraunhofer IGB |
| 2018 – 2020 | M. Sc. (Biochemistry) at Eberhard Karls University, Tübingen |
| 2014 – 2018 | B. Sc. (Biochemistry) at Eberhard Karls University, Tübingen |
| 2016 – 2017 | Study abroad at Capital Normal University and Tsinghua University, Beijing, China |
| Project title | Project title long | Funding source | Period |
| ImmuDarm | human organ models for testing products against chronic inflammatory bowel disease | Fraunhofer | January 2022 – December 2024 |
| Psoriceptors | Validation of innate immune receptors as targets for the treatment of psoriasis | BMBF | May 2020 – April 2022 |
| Immunsystem-to-go | Toll-like receptor assays – a new technology platform for Next Generation Immunoassays | BMBF | July 2019 – June 2022 |
| DAAD scholarship |
| YEAR | TITLE/AUTHOR |
| 2020 | Hans, F., Glasebach, H., & Kahle, P. J. (2020). Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. The Journal of biological chemistry, 295(3), 673–689. https://doi.org/10.1074/jbc.RA119.010617 |
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB